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Mitochondrial MKP1 Is a Target for Therapy-Resistant
HER2-Positive Breast Cancer Cells
Demet Candas1, Chung-Ling Lu1, Ming Fan1, Frank Y.S. Chuang2,3, Colleen Sweeney3,
Alexander D. Borowsky4, and Jian Jian Li1,5
Abstract
The MAPK phosphatase MKP1 (DUSP1) is overexpressed in many human cancers, including chemoresistant
and radioresistant breast cancer cells, but its functional contributions in these settings are unclear. Here, we
report that after cell irradiation, MKP1 translocates into mitochondria, where it prevents apoptotic induction by
limiting accumulation of phosphorylated active forms of the stress kinase JNK. Increased levels of mitochondrial
MKP1 after irradiation occurred in the mitochondrial inner membrane space. Notably, cell survival regulated by
mitochondrial MKP1 was responsible for conferring radioresistance in HER2-overexpressing breast cancer cells,
due to the fact thatMKP1 serves as amajor downstream effector in theHER2-activated RAF–MEK–ERKpathway.
Clinically, we documented MKP1 expression exclusively in HER2-positive breast tumors, relative to normal
adjacent tissue from the same patients. MKP1 overexpression was also detected in irradiated HER2-positive
breast cancer stem-like cells (HER2þ/CD44þ/CD24/low) isolated from a radioresistant breast cancer cell
population after long-term radiation treatment. MKP1 silencing reduced clonogenic survival and enhanced
radiosensitivity in these stem-like cells. Combined inhibition of MKP1 and HER2 enhanced cell killing in breast
cancer. Together, our ﬁndings identify a new mechanism of resistance in breast tumors and reveal MKP1 as a
novel therapeutic target for radiosensitization. Cancer Res; 74(24); 7498–509. 2014 AACR.
Introduction
Combined with surgery and chemotherapy, radiotherapy
continues to be a powerful tool in the treatment of breast
cancer (1); however, the therapy-resistant phenotype in recur-
rent and metastatic lesions accounts for major failure in many
patients and is the barrier for further improvement of the
efﬁcacy of anticancer therapy (2, 3). A prosurvival network
regulated by transcription factor NF-kB is responsible for a
fraction of breast cancer cells surviving long-term following
irradiation (4, 5). Radiation-induced NF-kBmediates the over-
expression of a novel prosurvival gene MAPK phosphatase 1
(MKP1), which is capable of inhibiting radiation-induced
apoptosis by attenuating JNK activity (5). Induction of MKP1
is controlled by the growth factor-induced activation of
MAPKs, ERK2/ERK1, suggesting an autoregulatory mecha-
nism (6). MKP1 is a direct substrate of ERK, which can
phosphorylate MKP1 on S359 and S364 (7) and increase its
half-life (6). MKP1 is also catalytically activated via ERK
binding to its N-terminal noncatalytic moiety (8), indicating
variousmeans of feedback exerted by active ERKonMKP1. The
role of MKP1 in HER2-overexpressing breast tumors is critical
as HER2 overexpression results in the hyperactivation of
MAPKs (9, 10), which in turn suggests potential increases in
the expression, stability, and activation of MKP1. Not surpris-
ingly, MKP1 has been shown to be overexpressed in human
breast cancer (11) and is implicated as a signiﬁcantmediator of
breast cancer chemoresistance (12).
Mitochondria play a crucial role in the regulation of cell
death, namely apoptosis (13). Cancer-speciﬁc mitochondrial
alterations are responsible for the resistance to mitochondria-
mediated apoptosis (5, 14). Many nuclear-encoded proteins
have been identiﬁed in the mitochondria of mammals to
regulate mitochondria-mediated apoptosis (14). Among the
MAPKs induced in response to irradiation, JNK was shown to
localize into mitochondria upon g-irradiation and initiate
mitochondria-mediated apoptosis via the phosphorylation of
Bcl-xl (15). JNK is targeted by MKP1 in irradiated cells to block
radiation-induced apoptosis, suggesting a potential prosurvi-
val role for MKP1 in mitochondria.
Recent evidence suggests that cancer stem cells (CSC) are
present in breast tumors (16) and are linked with tumor
resistance due to their increased survival (16–18). Al-Hajj and
colleagues and others showed that breast CSCswith the feature
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of CD44þ/CD24 aremore tumorigenic (16) under therapeutic
irradiation (19–26). Recentﬁndings fromour lab demonstrated
that HER2þ/CD44þ/CD24 breast CSCs are more aggressive,
invasive, tumorigenic, and radioresistant compared with
HER2/CD44þ/CD24 cells (22). Interestingly, we found that
HER2-positive breast CSCs overexpress MKP1 and depend on
MKP1 for survival.
Approximately 25% of human breast cancers overexpress
HER2, which is associated with poor prognosis and a more
aggressive phenotype in patients (27, 28). Current clinical
therapies targeting HER2 consists of the monoclonal antibody
trastuzumab and the tyrosine kinase inhibitor lapatinib
(29–31); however, due to adaptive resistance that tumors
acquire against anti-HER2 therapy, breast cancer recurrence
andmetastasis eventually develop in a fraction of patients with
HER2-positive breast cancer (27, 29, 32). It is an urgent need to
deﬁne alternative approaches to treat HER2-positive breast
tumors with therapy resistance and history of anti-HER2
therapy. Combination therapies targeting HER2 and therapy
resistance pathways could efﬁciently overcome the resistance
and potentially prevent the recurrence.
Herein, MKP1 was identiﬁed in the mitochondria of MEFs
and a variety of human cancer cells. The mitochondrial MKP1
was enhanced under genotoxic stress following g-irradiation
andwas able to dephosphorylate and inactivate mitochondrial
JNK, resulting in decreased apoptosis and radioresistance.
Furthermore, MKP1 expression in clinical breast tumor sam-
ples showed a strong correlationwithHER2 expression.MKP1-
mediated survival of breast cancer cells varied according to
their HER2 status. These data suggest MKP1 mitochondrial
localization as a mechanism of therapy resistance in breast
cancer and offers MKP1 as a potentially effective target for
resensitizing tumor cells for anticancer therapy.
Materials and Methods
Cell lines and clinical tumor samples
Wild-type (wt) and Mkp1/ (Mkp1 knockout) mouse
embryonic ﬁbroblasts (MEF) were kindly provided by Robert
Z. Orlowski at the University of North Carolina (Wilmington,
NC). These cells were maintained in DMEM supplemented with
10% FBS. MDA-MB-231, MCF7 wt, MCF7/HER2, and MCF7/C6
cells were kept in 1% nonessential amino acid containing MEM
supplemented with 10% FBS. SKBR3 cells were maintained in
RPMI1640 containing 10% FBS. HCT116 cells were obtained
from Dr. Bert Vogelstein at Johns Hopkins University (Balti-
more, MD) and kept in McCoy 5A supplemented with 10% FBS.
HER2þ/CD44þ/CD24/low and HER2/CD44þ/CD24/low cells
were sorted from an MCF7/C6 cell line and maintained in high
serum (20%) containing MEM media supplemented with 1%
nonessential amino acids. Clinical specimens were provided by
the UC Davis Comprehensive Cancer Center Biorepository,
which is funded by the NCI (Bethesda, MD).
Reagents and antibodies
U0126 was purchased from VWR International, JC-1 from
Invitrogen, Sanguinarine from Tocris Biosciences, and lapa-
tinib from Selleckchem. Antibodies for MKP1, ERK, pERK,
JNK, pJNK, HER2, and TOM40 were purchased from Sigma;
COXIV and pMKP1 were purchased from Cell Signaling
Technology.
Plasmids and siRNA
The details of recombinant plasmid construction and siRNA
synthesis are included in the Supplementary Information.
Mitochondria isolation
Cells were harvested and resuspended in buffer A (134
mmol/L NaCl, 5 mmol/L KCl, 0.7 mmol/L Na2HPO4, 2.5
mmol/L Tris HCl pH 7.5). After centrifugation at 600  g,
the pellet was resuspended in buffer B (10 mmol/L NaCl,
1.5 mmol/L MgCl2, 10 mmol/L Tris HCl pH 7.5) and the cells
were lysed using a glass homogenizer followed by the addition
of Buffer C (2mol/L sucrose, 35mmol/L EDTA, 50mmol/L Tris
HCl pH 7.5). Centrifugation at 600 g removed cell debris and
the supernatant was centrifuged at 10,000 rpm to pellet the
mitochondria. The pellet was washedwith buffer D (0.33mol/L
sucrose, 1 mmol/L EDTA, 8.3 mmol/L Tris HCl pH 7.5), lysed,
and stored.
Alkaline extraction and mitoplasting
Alkaline extraction was performed as previously reported
(33). Brieﬂy, the mitochondria was incubated in 0.1 mol/L Na2
CO3 (pH 11) for 20 minutes at 4C. The membrane was then
centrifuged at 100,000  g. Proteins in the supernatant were
precipitated using a ﬁnal volume of 10% trichloroacetic acid
(TCA). The pellets were resuspended in dissolving buffer
containing 7 mol/L urea, 3 M thiourea, 2% CHAPS, 30
mmol/L Tris, pH 8.5. Mitoplasting was performed by diluting
mitochondria in hypotonic sucrose buffers (1 mmol/L EDTA,
10mmol/LMOPS-KOH, pH 7.2; sucrose concentration ranging
from 25 mmol/L to 200 mmol/L) with or without 50 mg/mL
soybean trypsin. Proteolysis was stopped by adding 1 mmol/L
phenylmethylsulfonylﬂuoride. The mitoplasts were separated
by centrifugation at 16,000  g. Pellets were lysed and all
supernatant fractions were precipitated with 10% TCA and
resuspended in dissolving buffer.
Mitochondrial membrane potential assay (Dcm)
Cells (104 cells/well) were seeded on 96-well plates and
treated with 10 Gy or 0 Gy irradiation. At indicated time points,
2 mg/mL of JC-1 dyewas added for 30minutes at 37C. Cationic
dye taken up bymitochondriawas detected by the formation of
red precipitate in the cells. The dye was excluded and detected
as a green monomer in the cytoplasm of the cells with
disrupted mitochondria. After washing with PBS (pH 7.4), the
ﬂuorescence intensity of the red precipitate (JC-1 red) and
green monomer (JC-1 green) were detected using a Spectra
Max M2e plate reader (Molecular Devices Co.) at excitation
485/emission 595 or excitation 485/emission 525, respectively.
The ratio of JC-1 red/JC-1 green was calculated as Dcm.
Immunoprecipitation
Approximately 107 cells were incubated with 10 mL of
protein A/G agarose beads (Roche) and normal IgG at 4C for
1 hour for preclearance. After centrifuging at 1,000 rpm, the
supernatant was incubated with 10 mg of antibody overnight at
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4C. Subsequently, 50 mL of protein A beads was added for 1
hour at 4C to capture the antibody–protein complexes. The
mixture was then spun to collect the beads. After the beads
were washed four times with lysis buffer, 1 protein sample
buffer was added and the beads were boiled at 95C for
10 minutes to separate beads and the pulled down proteins.
BCSC sorting
Following described procedures (16), the cell suspensions
were rinsed with PBS with 2% FBS, resuspended in PBS
containing 0.5% FBS and PI (0.5 mg/mL) and sorted using the
Cytopeia inﬂux Cell Sorter (BD Biosciences).
Trypan blue assay
Cells were collected in PBS, and 4%Trypan blue solutionwas
added to the cells. The percentage of viable cells was deter-
mined by counting the cells that are white (live cells that have
excluded the dye) and blue (dead cells that cannot exclude the
dye) under the microscope using a hematocytometer.
Clonogenic survival assay
The standard clonogenic survival assay was performed as
previously described (4). Survival fraction was assessed by
colony formation following exposure to sham or 10 Gy of
radiation. The colonies were stained with Coomassie blue,
and colonies with more than 50 cells were scored and nor-
malized against the plating efﬁciency of cells.
Statistical analysis
The data are presented as means  SE; ﬁndings were
considered signiﬁcant at P < 0.05.
Results
MKP1 translocates into mitochondria and inhibits
proapoptotic signals from JNK
Mitochondrial fractions isolated from irradiated MEFs
showed that mitochondrial MKP1 levels increased after 10 Gy
irradiation until 4 hours postirradiation, and then gradually
returned to basal levels (Fig. 1A, top), whereas the overall
expression ofMKP1 remained constant until after 8 hours after
irradiation (Fig. 1A, bottom). The purity of mitochondrial
preparations was conﬁrmed by the absence of markers of
other cellular compartments such as cytoplasm, nucleus, and
Golgi, in the mitochondrial preparations (Fig. 1B). The alkaline
extraction method (33) was used to prepare submitochondrial
fractions to determine the mitochondrial sublocalization of
MKP1. After alkaline extraction, membrane proteins are
retained in the pellet while soluble proteins are recovered in
the supernatant. TIMM13 subunit of the translocase of inner
membrane complex, TOM40 subunit of the translocase of
outer membrane complex, and HSP60 chaperon were utilized
as markers of the submitochondrial compartments; inner
membrane space (IMS), outer membrane, and matrix,
respectively. The results indicated that MKP1 is either a
soluble protein that localizes into the matrix like HSP60, or
an integral membrane protein that localizes into the inner
membrane like TIMM13 (Fig. 1C). To further deﬁne
the submitochondrial location of MKP1, mitoplasting was
performed by diluting mitochondria in hypotonic buffers
with decreasing concentrations of the osmoticum sucrose
from 200 mmol/L to 25 mmol/L. The outer membrane began
to rupture at 200 mmol/L of sucrose, whereas the inner
membrane remained intact until the ﬁnal concentration at
25 mmol/L of sucrose (Fig. 1D). In combination with mito-
plasting, a protease protection assay was performed using
trypsin to digest exposed proteins after outer membrane
rupture. While HSP60 was protected from trypsin digestion,
MKP1, similar to TIMM13, was digested in the supernatant
of the trypsin-treated samples, indicating its mitochondrial
IMS localization (Fig. 1D).
Elevation of mitochondrial MKP1 levels correlated with an
increase in the mitochondrial membrane potential when com-
pared with basal levels in untreated sham control cells. At peak
accumulation ofMKP1 in themitochondria (4 hours post-IR), a
higher mitochondrial membrane potential, indicative of lower
apoptosis, was observed (Fig. 1E). Cleaved caspase-3 levels
(Fig. 1F) and cytochrome c release (Fig. 1G) were both reduced
at 4 hours post-IR compared with their levels in untreated
shamcontrol cells. The reduced levels of apoptosis ofMEFs at 4
hours post-IR, as shown by reduced caspase cleavage and
cytochrome c release to cytoplasm, may have resulted from
increased levels of MKP1 and consequently, reduced phos-
phorylated JNK (pJNK) levels in the mitochondria (Fig. 1H). To
further address whether mitochondrial MKP1 targets pJNK in
irradiated cells, we compared the pJNK levels in the mitochon-
dria of wild-type (wt) and MKP1/ MEF cells upon irradia-
tion. As expected, pJNK levels were higher in the mitochondria
of MKP1 knockout cells (Fig. 1I). These cells exhibited dra-
matically low clonogenic survival ability when compared with
wt MEF cells following irradiation (92% lower survival). While
the absence of MKP1 alone resulted in 29% lower survival in
nonirradiated cells, irradiation alone caused 39% lower sur-
vival in wt MEFs and 88% lower survival in MKP1 knockout
cells, indicating the importance of MKP1 for survival following
irradiation (Fig. 1J). Taken together, these data show that
MKP1 translocates into the IMS of mitochondria upon irra-
diation and functions to attenuate proapoptotic signals from
pJNK, leading to increased survival.
Mitochondrial localization of MKP1 in breast cancer
cells
To evaluate whether MKP1 translocation tomitochondria is
a survival strategy also adopted by other cells, we tested the
radiation-induced mitochondrial localization of MKP1 in a
variety of normal and cancer cells. InMCF7 breast cancer cells,
mitochondrial MKP1 levels were increased shortly after irra-
diation, 1 to 2 hours, and then returned to basal levels, whereas
the total MKP1 levels remained unchanged (Fig. 2A). Mito-
chondrial MKP1 localization was also observed in MDA-MB-
231 and SKBR3 breast cancer cell lines (Fig. 2B) and in HK18
human skin keratinocytes (data not shown). Although with
different dynamics, MKP1 was also localized to mitochondria
in HCT116 colon cancer cells at 8 hours post-IR (Fig. 2C).
Coimmunoprecipitation experiments showed that MKP1
physically interacts with JNK in the mitochondria of MCF7
cells (Fig. 2D). These data indicatemitochondrial translocation
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ofMKP1 as a common survival strategy for diversemammalian
cell types, including normal mouse (MEF) and human tumor
cells.
MitochondrialMKP1 levels are elevated in radioresistant
breast cancer cells
The prosurvival role of mitochondrial MKP1 points to its
potential role in radioresistance. We compared the mitochon-
drial MKP1 levels inMCF7/HER2 (HER2-overexpressing radio-
resistant cells), MCF7/C6 (FIR-derived radioresistant cells;
ref. 4) and wt MCF7. As expected, MKP1 translocation to
mitochondria was enhanced in the radioresistant breast can-
cer cells (Fig. 2E). In accordancewith the previous results, these
radioresistant cells showed low levels of mitochondrial phos-
phoJNK, indicating that MKP1 may contribute to the radio-
resistance of breast cancer cells by blocking the proapoptotic
Figure 1. Mitochondrial MKP1 is enhanced by genotoxic stress in MEFs to inhibit mitochondria-initiated apoptosis via reduction of pJNK. A, mitochondrial
translocation of MKP1 in sham or 10 Gy irradiated MEFs. COXIV was used as the marker for mitochondria and IkB was used as the cytoplasmic marker.
B, the purity of mitochondrial preparations in these experiments was further analyzed by immunoblots of MKP1, COXIV, a-tubulin (cytoplasmic
marker), histone H3 (nuclear marker), and giantin (Golgi marker). C, submitochondrial localization of MKP1 detected by alkaline extraction (33). Total input (T),
soluble matrix proteins (S), and membrane pellets (P) were immunoblotted for MKP1, TOM40 (an outer membrane protein), TIMM13 (an interspace
protein), and HSP60 (a matrix protein). D, submitochondrial localization of MKP1 detected via mitoplasting and protease protection assay (49). The
total (T), pellet (P), and supernatant (S) fractions were subjected to Western blotting with indicated antibodies. Dcm (E, measured by ﬂuorescent probe
JC-1; n ¼ 3, P < 0.01), caspase 3 cleavage (F), and cytochrome c release (G) in sham or 10 Gy irradiated MEFs. H, increased MKP1 and decreased pJNK
levels in mitochondrial fractions 4 hours after 10 Gy IR. I, JNK phosphorylation in the mitochondria of Mkp1 knockout and wt MEFs 4 hours after 10 Gy of
radiation. pJNK levels were normalized to that of JNK levels and represented under the blots. J, clonogenic survival analysis of wt versus Mkp1/ MEFs
(n ¼ 3; , P < 0.05; , P < 0.01).
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activity of pJNK (Fig. 2E). The mitochondrial membrane
potential of radioresistant cell lines was signiﬁcantly higher,
consistent with the lower levels of apoptosis expected in
radioresistant cells with decreased mitochondrial pJNK
(Supplementary Fig. S1).
ERK1/2 is an upstream regulator of MKP1 in breast
cancer cells
Similar to many cell signaling molecules, MKP1 is also
regulated by phosphorylation/dephosphorylation events
(6, 7). One of the upstream regulators of MKP1 was identiﬁed
as ERK1/2, which binds to and phosphorylatesMKP1 at Ser359
(7, 8). Thus, we addressed whether ERK is responsible for
activation of MKP1 in MCF7 cells. The phosphorylated ERK
levels were higher in radioresistant breast cancer cells com-
paredwithwtMCF7 following irradiation (Fig. 2F), indicating a
potential role for active ERK1/2 in radioresistance. The anal-
ysis of mitochondrial fractions isolated from MEK inhibitor
(U0126)-treated cells revealed that mitochondrial localization
of MKP1 was reduced by ERK inactivation, while the expres-
sion of MKP1 remained constant (Supplementary Figs. S2 and
S2G). Mitochondrial MKP1 was found to be serine phosphor-
ylated (Fig. 2H), and mitochondrial JNK was shown to interact
with Ser359-phosphorylated MKP1 (Fig. 2I). While Ser359
phosphorylation of MKP1 was enhanced in cells as early as
1 hour post-IR (Fig. 2J), the mitochondrial MKP1 phosphory-
lation was increased at 2 hours post-IR (Fig. 2K). Together, the
results suggest that ERK-dependent phosphorylation/activa-
tion of MKP1 may be required for translocation of MKP1 into
the mitochondria.
MKP1 expression inHER2-expressing breast cancer stem
cells and clinical breast tumor samples
Next, we analyzed six pairs of normal and tumor tissue
samples from six patients with breast cancer for MKP1 expres-
sion (Fig. 3A). MKP1 expression was induced in tumor tissues
in 4 of the patients tested, while their normal tissues lacked
MKP1 (patients 1, 2, 4, and 5). One patient showed reduced
Figure 2. ERK1/2-dependent
mitochondrial localization and
phosphorylation of MKP1 under
radiation insult. Immunoblots of
mitochondrial MKP1 in IR-treated
breast cancer MCF7 (A), MDA-MB-
231 and SKBR3 (B) cells, and
colon cancer HCT116 cells (C).
D, coimmunoprecipitation of
mitochondrial MKP1 and JNK in
sham or IR-treated MCF7 cells.
E, enhanced mitochondrial MKP1
and decreased pJNK levels in
radioresistant MCF7/C6 and
MCF7/HER2 cells compared with
wtMCF7s. F, pERK and ERK levels
in sham or 10 Gy irradiated wt and
radioresistant MCF7s. G, MKP1
mitochondrial translocation was
inhibited by the MEK inhibitor,
U0126. MCF7 cells were
pretreated with 10 mmol/L of
U0126 for 1 hour before IR and
harvested 2 hours post-IR. H and I,
ERK-mediated phosphorylation
of MKP1 determined via
coimmunoprecipitation using anti-
MKP1 for immunoprecipitation
(IP) and anti-pSer antibody for
immunoblotting (IB; H); and
anti-JNK for immunoprecipitation
and anti-pMKP for immunoblotting
(I). J and K, MKP1 phosphorylation
in irradiatedMCF7cells (J) and their
mitochondria (K).
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MKP1 levels in tumor tissue (Patient 6), while MKP1 was
overexpressed in the normal tissue. Although there is no
consensus for the expression of MKP1 being speciﬁc to normal
or tumor tissues within the limits of small sample size, MKP1
expression strictly correlated with HER2 expression in these
patients (Fig. 3A). HER2-overexpressing tumors also exhibited
MKP1 overexpression (patients 1, 2, 4, and 5), and patients that
lost HER2 expression in their tumors also lost MKP1 expres-
sion (patient 6). We then tested the expression of MKP1 in a
panel of clinical tumor samples with differential HER2 status.
The results showed thatMKP1 expression is limited exclusively
to HER2-positive tumors (Fig. 3B). MKP1 phosphorylation was
also observed in these HER2-positive samples.
A recent study showed that HER2-positive breast cancer
stemcells (BCSC), HER2þ/CD44þ/CD24/low, are radiotherapy
resistant (22). We analyzed the expression of MKP1 in HER2-
positive and HER2-negative BCSCs, originally isolated from
MCF7/C6 cells, with or without irradiation. The results showed
that although the basal MKP1 expression was low in both
HER2-positive and HER2-negative BCSCs, MKP1 expression
was greatly induced in irradiated HER2þ/CD44þ/CD24/low
cells (Fig. 3C). Knocking down MKP1 in HER2þ/CD44þ/
CD24/low cells resulted in reduced survival (35% decrease),
while irradiation alone caused a 70% decrease (Fig. 3D).
Irradiation of MKP1-depleted HER2-positive BCSCs resulted
in a dramatic reduction in their clonogenic survival (95%
decrease), indicating a role for radiation-induced MKP1 in the
radioresistant phenotype of HER2-positive BCSCs. These
results suggest that MKP1 expression may be regulated by
HER2 to manage the therapy resistance of HER2-expressing
breast cancer cells.
MKP1 is required for breast cancer cell survival
The role of MKP1 in radioresistance of breast cancer cells
was further studied via MKP1 siRNA treatment of wt or
radioresistant MCF7 cells (Fig. 4A). Knockdown of MKP1 in
MCF7 cells resulted in a 51% decrease in their survival, while
radiation treatment reduced their survival by 64%. Together,
irradiation and MKP1 depletion caused 89% reduction in the
survival of breast cancer MCF7 cells (Fig. 4B). The knockdown
of MKP1 in radioresistant MCF7/C6 cells resulted in a 45%
reduction in clonogenic survival, radiation treatment alone
caused a 60% decrease, whereas the combination of MKP1
siRNA treatment plus irradiation resulted in a dramatic 78%
decrease (Fig. 4C). These results indicate thatMKP1 is required
for the survival of breast cancer cells and knockdown of MKP1
can resensitize radioresistant breast cancer cells.
The strong correlation of HER2 and MKP1 expression in
breast cancer encouraged us to test the MKP1-mediated
survival mechanism in a panel of breast cancer cells with
differential HER2 status. We utilized MCF7 wt (HER2-low),
MDA-MB-231 (HER2-negative), SKBR3 (HER2-positive),
MCF7/C6 (HER2-overexpressing), and HER2þ/CD44þ/
CD24/low (HER2-positive BCSCs). The results showed that
HER2-positive breast cancer cells weremore sensitive toMKP1
siRNA treatment compared with HER2 low/negative cell lines,
as they exhibited massive cell death after 48 hours of siRNA
treatment (Supplementary Fig. S3A and S3B). Comparison of
the clonogenic survival of the HER2-negative MDA-MB-231
and HER2-overexpressing SKBR3 cells revealed that knocking
down MKP1 in both MDA-MB-231 and SKBR3 cells reduced
their clonogenic survival; however, the effect of MKP1 inhibi-
tion in SKBR3 cells (65%) was signiﬁcantly greater than that
ofMDA-MB-231 cells (20%; Fig. 4D andE).MDA-MB-231 cells
were highly radiosensitive and knockdown of MKP1 in these
cells did not further change their clonogenic survival upon
irradiation. In contrast, SKBR3 cell survival was greatly
reduced byMKP1 siRNA treatment after irradiation, indicating
that HER2-positive breast cancer cells may rely more onMKP1
for survival than their HER2-negative counterparts. Even
Figure 3. Coactivation of HER2 and
MKP1 in HER2þ and HER2 breast
cancer tissues and radioresistant
HERþ breast cancer stem cells
(HER2þ BCSCs). A, the
coexpression of HER2 and MKP1
in a panel of paired human normal
and tumor breast tissues (N, tumor
surrounding normal breast tissue).
B, the expression ofMKP1, pMKP1
(S359), and HER2 in clinically
diagnosed breast cancer patients
with differential HER2 status. C,
MKP1 expression levels in HER2þ
/CD44þ/CD24 and
HER2/CD44þ/CD24 breast
cancer stem cells (HER2þ BCSCs
and HER2 BCSCs) that were live-
sorted from MCF7/C6 cells
according to Duru and colleagues
(22). D, clonogenic survival of
HER2þ breast CSCs with or
without MKP1 siRNA transfection
(n ¼ 3; , P < 0.01).
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though MKP1 depletion dramatically reduced the survival of
the cells, bothwt andMKP1 siRNA-treated cells showed similar
reduction in their survival after irradiation. This may have
resulted from the compensation by the residual MKP1 in these
knockdown cells as the siRNA-mediated knockdown did not
completely wipe out MKP1 from the cells (Fig. 4A).
Furthermore, we utilized a selective inhibitor of MKP1,
sanguinarine (34), and tested cell survival in a variety of breast
cancer cell lines after inhibitor treatment. The optimum time
and concentration of sanguinarine to be used was determined;
5 mmol/L and 10 mmol/L sanguinarine killed 50% and 75% of
SKBR3 cells as early as 2 hours (Supplementary Fig. S4).
A similar pattern was observed with MCF7/C6 cells (Supple-
mentary Fig. S5). The comparison of cell killing ability of MKP1
inhibitor revealed that all breast cancer cell lines are sensitive
to sanguinarine treatment (Fig. 5A–D); however, MDA-MB-231
cells were slightly less sensitive to MKP1 inhibition, suggesting
HER2-expressing cell lines may rely more onMKP1 for survival
thanHER2-negative cells. The clonogenic survival of these cells
conﬁrmed that the cells treated with MKP1 inhibitor showed
reduced clonogenic ability compared with no treatment and
solvent control cells (Fig. 5E). Sanguinarine treatment alone
resulted in 70%, 80%, and 74% decrease in the survival of
MCF7/C6, MCF7 wt, and SKBR3 cells, respectively; while
radiation treatment alone reduced their survival by 77%,
78%, and 82%. Combination of inhibitor and radiation treat-
ment resulted in 90% reduction in their survival rate.
Finally, to determine whether MKP1 overexpression pro-
vides a survival advantage to breast cancer cells, we con-
structed a GFP-tagged MKP1 vector and transfected MCF7
and SKBR3 cells (Fig. 5F and G, left). Overexpression of MKP1
did not provide a signiﬁcant survival advantage to MCF7 cells
with or without irradiation (Fig. 5F, right); however, SKBR3
cells showed signiﬁcant enhancement in their clonogenic
survival ability after radiation treatment when MKP1 is over-
expressed (85% recovery in survival; Fig. 5G, right). These
results suggest that the MKP1-mediated survival mechanism
may require HER2 expression to be activated. It is likely that
MCF7 cells with low HER2 expression are not able to activate
overexpressed GFP-MKP1 to exhibit the expected levels of
enhanced survival. Conversely, SKBR3 cells with HER2 over-
expression were able to take advantage of enhanced MKP1
levels to survive the subsequent radiation insult. All in all, the
data suggest that HER2 expressing cells depend on MKP1 for
survival, demonstrating MKP1 as a potential target in HER2-
positive breast cancer for tumor control.
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Targeting MKP1 and HER2 for efﬁcient killing of breast
cancer cells
The role of MKP1 in the survival of HER2-positive breast
cancer cells suggested that combinatory targetting of MKP1
and HER2 may provide more efﬁcient cell killing than HER2
inhibition alone. We treated the MCF7/C6 (Fig. 6A), SKBR3
(Fig. 6B), and MCF7 wt (Fig. 6C) cells with increasing con-
centrations of lapatinib (a clinically usedHER2 inhibitor) alone
or in combination with MKP1 siRNA to test whether MKP1
depletion would provide any beneﬁt over lapatinib alone.
Inhibition of MKP1 along with lapatinib treatment further
reduced the viability in HER2-expressing breast cancer cells
(Fig. 6A–Cand Supplementary Fig. S6). A similar combinatorial
treatment targeting study with HER2 siRNA and MKP1 inhib-
itor, sanguinarine, resulted in increased cell killing in breast
cancer cells compared with HER2 siRNA treatment alone
(Fig. 6D and F). Finally, we explored the efﬁcacy of combination
of chemo- and radiotherapy in HER2-positive breast cancer
cells and breast cancer stem cells using a combination of
sanguinarine and lapatinib inhibitors and IR (Fig. 6G–I). The
results revealed that the combination of sanguinarine and
lapatinib killed more cells, which was further exacerbated by
radiation treatment. Lapatinib inhibits the receptor tyrosine
kinase activity of HER2 (35), which is also shown here by the
inhibition of phosphorylation of downstream effector ERK
(Supplementary Fig. S7A). Expectedly, lapatinib treatment
resulted in decreased mitochondrial localization of MKP1
(Supplementary Fig. S7B), which accounts for the reduced
survival of lapatinib-treated cells. These combinatorial treat-
ment studies performed in a panel of breast cancer cell lines
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demonstrated that combination therapy is a more efﬁcacious
anticancer strategy than the individual inhibition of MKP1 or
HER2 in the control of breast cancer.
Discussion
This study reveals a mechanism by which MAPK phospha-
tase, MKP1, mediates a prosurvival response in breast cancer
cells overexpressing HER2 (Fig. 7), suggesting an alternative
therapeutic approach for HER2-positive tumors, especially the
recurrent and metastatic tumors with an acquired resistance
to previously administered anti-HER2 therapy. MKP1 expres-
sion was found to correlate with HER2 expression in breast
cancer stem cells and clinical breast tumor specimens. Com-
parison of MKP1 inhibition in a panel of breast cancer cells
with differential HER2 status revealed that HER2-positive
breast cancer cells rely on MKP1 for survival. Therefore,
targeting of MKP1 along with HER2 in HER2-expressing breast
cancer cells resulted in increased cell killing and suggest MKP1
as a therapeutic target for controlling breast cancer cell
survival. The data showing that MKP1 is overexpressed in
HER2-expressing breast tumors, but not in the adjacent nor-
mal tissue of the same patients, suggest that MKP1 may be a
potential target to treat resistant breast tumors with minimal
side effects to the normal tissue. Our current studies reveal that
MKP1 is not only expressed in clinical tumor tissues compared
with their counterpart normal tissues from the same patients,
but also that MKP1 is signiﬁcantly enhanced in tumor cells
under the stress of therapeutic radiation (5). Although a larger
cohort of patient studies will be essential to further investigate
the expression of MKP1 in tumor and normal tissues, our data
clearly indicate that MKP1 is an important survival protein in
breast cancer cells and a critical downstream element of HER2
signaling.
Elucidation of the mechanism by which MKP1 functions in
breast tumorsmay prove to be beneﬁcial in the clinic. It will be
of great importance to understand why radiation-induced
MKP1 particularly targets JNK of the three MAPKs (5). MKP1
dephosphorylates proteins of theMAPK family in the following
order of afﬁnity: p38MAPK  JNK >> ERK1/2 (36–38).
Although MKP1 binding to ERK1/2 and p38aMAPK relies on
the same arginine residues (arginine 53–55; ref. 39), its binding
to JNK depends on presently unidentiﬁed residues within the
ﬁrst N-terminal 188 residues of MKP1 and not arginine 53–55
(8). This may have implications for why radiation-induced
MKP1 speciﬁcally targets JNK (5). Nevertheless, the identiﬁ-
cation of the MKP1 residues that are responsible for its
interaction with JNK may be beneﬁcial for eventual therapeu-
tics. More importantly, the ability to interfere with binding of
each MAPK to MKP1 independently will contribute greatly to
the clinic. The role of ERK MAPK in the induction of MKP1
mitochondrial translocation suggests that hindering the inter-
action between ERK and MKP1 may be a valuable strategy to
block the survival pathway initiated by MKP1 to increase cell
death.
MKP1 is currently believed to be a nuclear phosphatase with
its dephosphorylating activity restricted to within the nucleus
(36, 40). MKP1 is targeted to the nucleus via its LXXLL motif
(40), which is different than any known consensus nuclear
targeting sequences (41, 42). How MKP1 is targeted to the
nucleus, whether on its own or via binding to a facilitator
molecule, remains elusive. In addition to literature on nuclear
MKP1, our study revealed MKP1 localization into the
mitochondria. MKP1 lacks anN-terminalmitochondria target-
ing sequence, which suggests the presence of an internal
targeting sequence. Proteinswithout N-terminalmitochondria
targeting sequences are translocated into themitochondria via
binding to HSPs and/or 14-3-3 chaperons (43). The elucidation
of the detailed mechanisms underlying nuclear or mitochon-
drial targeting of MKP1 will offer additional control over
this phosphatase via the regulation of its intracellular locali-
zation. The possibility of sequestering MKP1 in the cytosol
as a means to limit its phosphatase activity in the mitochon-
dria, via modiﬁcation of the molecules involved in its mito-
chondrial localization, carries a great potential for anticancer
therapeutics.
Lapatinib is a reversible inhibitor of the tyrosine kinase
activity of HER2 and EGFR (27, 30); however, its antitumor
activity in breast cancer is more dependent on HER2 over-
expression than EGFR (44, 45). Although lapatinib and other
HER2-targeting agents produce a positive outcome in breast
cancer patients, the development of acquired resistance inev-
itably causes a fraction of these tumors to recur. Understand-
ing the survival networks underlying the acquired resistance
may enable the use of agents targeted against these prosurvival
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Figure 7. Activation of HER2/ERK/MKP1 pathway in therapy-resistant
breast cancer cells. We have previously reported that radiation therapy
induces the expression of HER2 and MKP1 via NF-kB–mediated gene
promoter activation in breast cancer cells (4, 5, 50). Here, we identiﬁed
that MKP1 mitochondrial relocation is enhanced by radiation to target
mitochondrial pJNK. The dephosphorylation and inactivation of JNK led
to the attenuation of the pro-apoptotic signals from JNK, resulting in the
inhibition of mitochondria-mediated apoptosis and radioresistant
phenotype of breast cancer cells with HER2 status, including the HER2-
positive breast cancer stem cells. The mitochondrial MKP1 is thus a
potential target for therapy-resistant breast cancer cells, especially for
recurrent/metastatic lesions with adaptive resistance to anti-HER2
therapy.
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pathways and yield clinically relevant neoadjuvant regimens to
improve the efﬁcacy of anticancer treatment. Identiﬁcation of
an MKP1-mediated prosurvival pathway downstream of HER2
in breast cancer cells reveals MKP1 as a rational candidate for
targeted agents. The availability of a selective MKP1 inhibitor,
sanguinarine (34), is a valuable tool for the assessment of
combination strategies to overcome tumor resistance.
This study showed thatHER2-positive breast cancer cells are
exclusively dependent onMKP1 for their survival. This could be
a signiﬁcant ﬁnding as approximately 50% of patients that
receive chemotherapy are also given radiotherapy (46), sug-
gesting that combinatorial strategies using speciﬁc molecules
to inhibit the cell-protecting function of MKP1 along with
conventional chemo- or radiotherapy may offer a better anti-
cancer approach. In human breast cancers, there is a strong
correlation between the expression of the HER2 oncogene and
ERK1/2 and MKP1 protein expression (47). It is suggested that
HER2, by stimulating the Raf–MEK–ERK pathway (48), pro-
tects ERK1/2 from inactivation by MKP1. This scenario can be
deleterious when considering our ﬁndings that ERK is
upstream of MKP1 mitochondrial localization. Constitutive
ERK activation in HER2-overexpressing breast cancers would
result in enhanced MKP1 mitochondrial localization and
increased survival. In accordance with this scenario, we found
that MKP1 is overexpressed in HER2-overexpressing breast
cancer stem cells. Targeting MKP1 by siRNAs or chemical
inhibitors in a variety of breast cancer cells proved to be an
efﬁcient mechanism to sensitize breast cancer cells to radia-
tion and chemotherapy. In the clinic, it has been well observed
that many patients with breast cancer develop tumor resis-
tance to anti-HER2 therapy (27, 29–31). Our combinatorial
inhibition studies showed that targeting of MKP1 and HER2
together is a more efﬁcient anticancer strategy and that the
addition of radiotherapy to the chemical inhibition of MKP1
and HER2 further reduced tumor cell survival. Further eluci-
dation of the mechanisms of the HER2-MKP1 prosurvival
networkmay generate alternative approaches to treat resistant
breast cancer.
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